[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100453223":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":27,"centralContacts":31,"locations":40,"responsibleParty":57,"collaborators":59,"id":62,"slug":63,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":68,"eligibilityCriteria":69,"healthyVolunteers":70,"sex":71,"minAge":72,"maxAge":73,"enrollmentInfo":74,"targetDuration":18,"studyType":77,"phases":78,"briefSummary":81,"conditions":82,"keywords":89,"overallStatus":42,"whyStopped":18,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":103},{"fullName":5,"class":6},"Genesis Athens Clinic","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Experimental: Group of participants receiving PRP treatment","EXPERIMENTAL","Women presenting with POR, treated with autologous PRP intraovarian infusion during the mid-luteal phase, undergoing a subsequent stimulated fresh ET-ICSI cycle on the first month following PRP infusion",[13],"Biological: Autologous platelet rich plasma",{"label":15,"type":16,"description":17,"interventionNames":18},"Control Group: Group of participants receiving standard protocol","NO_INTERVENTION","Women presenting with POR undergoing a stimulated fresh ET-ICSI cycle",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"BIOLOGICAL","Autologous platelet rich plasma","Preparation of PRP will be performed immediately following blood sample collection. Blood samples will be collected from the median antebrachial vein. PRP will be prepared according to the manufacturer's instructions employing a Regen Autologous Cellular Regeneration (ACR®-C) Kit (Regen Laboratory, Le Mont-sur-Lausanne, Switzerland). Approximately 60 mL of the patient's peripheral blood will be required in order to yield the required volume of PRP. The goal concentration of platelets in PRP is approximately 1.000.000 platelets\u002FµL. The technique of PRP intraovarian infusion resembles the transvaginal paracentesis performed during the oocyte pick-up procedure. Briefly, both ovaries are visualized via transvaginal ultrasound monitoring, and they are intramedullary injected on multiple sites using a 17-gauge single lumen needle, with the patient under inhaled minimal sedation.",[9],[26],"PRP",[28],{"name":29,"affiliation":5,"role":30},"Agni Pantou, M.D","PRINCIPAL_INVESTIGATOR",[32,36],{"name":29,"role":33,"phone":34,"phoneExt":18,"email":35},"CONTACT","+306974447702","agni.pantou@genesisathens.gr",{"name":37,"role":33,"phone":38,"phoneExt":18,"email":39},"Konstantinos Pantos, M.D., Ph.D","+302106894326","info@pantos.gr",[41],{"facility":5,"status":42,"city":43,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"RECRUITING","Athens","Attica","15232","Greece","GR",{"type":49,"coordinates":50},"Point",[51,52],23.72784,37.98376,{"lat":52,"lon":51},[55,56],{"name":29,"role":33,"phone":34,"phoneExt":18,"email":35},{"name":29,"role":30,"phone":18,"phoneExt":18,"email":18},{"type":58,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR",[60],{"name":61,"class":6},"National and Kapodistrian University of Athens","100453223","phase-2-autologous-platelet-rich-plasma-intraovarian-infusion-for-poor-responders-100453223",false,"NCT05181748","Autologous Platelet Rich Plasma Intraovarian Infusion for Poor Responders","Investigating the Efficiency of Autologous Platelet Rich Plasma Intraovarian Infusion on Improving Ovarian Functionality in Poor Ovarian Response Patients","PRPPOR","Inclusion Criteria:\n\nPoor Ovarian Response according to Bologna Criteria (fulfilling 2 out of 3 of the following):\n\n1. Age ≥ 40 years\n2. AMH \\\u003C 1.1 ng\u002Fml OR AFC \\\u003C 7\n3. ≤ 3 oocytes with a conventional stimulation protocol\n\n   * Discontinuation of any complementary\u002Fadjuvant treatment including hormone replacement and acupuncture, for at least three months prior to recruitment.\n   * Willing to comply with study requirements\n\nExclusion Criteria:\n\n* Any pathological disorder related to reproductive system anatomy\n* Cycle irregularities\n* Amenorrhea\n* Endometriosis\n* Adenomyosis\n* Fibroids and adhesions\n* Infections in reproductive system\n* Current or previous diagnosis of cancer in reproductive system\n* History of familiar cancer in reproductive system\n* Severe male factor infertility\n* Prior referral for Preimplantation Genetic Testing (PGT) -Ovarian inaccessibility -Endocrinological disorders (Hypothalamus-\n* Pituitary disorders, thyroid dysfunction, diabetes mellitus, metabolic syndrome)\n* BMI\\>30 kg\u002Fm2 or BMI\\\u003C18.5 kg\u002Fm2\n* Systematic autoimmune disorders",true,"FEMALE","35 Years","47 Years",{"count":75,"type":76},100,"ESTIMATED","INTERVENTIONAL",[79,80],"PHASE2","PHASE3","Autologous platelet rich plasma (PRP) intraovarian infusion may improve ovarian response to controlled ovarian stimulation as well as the hormonal profile of poor ovarian response infertile women subjected to intracytoplasmic sperm injection (ICSI) treatment.",[83,84,85,86,87,88],"Poor Response to Ovulation Induction","Infertility, Female","Ovarian Insufficiency","Ovarian Failure","Reproductive Sterility","Ovary; Anomaly",[90,91,26,92,93],"Autologous platelet rich plasma intraovarian infusion","Assisted reproduction","In vitro fertilization","Ovarian functionality improvement","2024-12-20",{"date":96,"type":97},"2024-12-27","ACTUAL",{"date":99,"type":97},"2019-01-23",{"date":101,"type":76},"2026-01-31",{"name":5,"class":6},1]